TABLE I.
Overall Outcomes Over Three Consecutive Children's Oncology Group Phase III Trials
| COG AML study in de novo AML | OS | EFS | RRa | TRMa | DFS from EOI | RR from EOI | TRM from EOI |
|---|---|---|---|---|---|---|---|
| POG-9421 [29] | 50 ± 4% (n = 565) | 37 ± 4% (n = 565) | 55 ± 4% (n = 565) | 8 ± 2% (n = 565) | 43 ± 5% (n = 475) | 51 ± 5% (n = 475) | 6 ± 2% (n = 475) |
| CCG-2961 post-susp [9] | 58 ± 5% (n = 406) | 46 ± 5% (n = 406) | 41 ± 5% (n = 406) | 12 ± 3% (n = 406) | 56 ± 6% (n = 269) | 38 ± 6% (n = 269) | 6 ± 3% (n = 269) |
| COG AAML03P1 [3] | 64 ± 5% (n = 340) | 51 ± 6% (n = 340) | 40 ± 5% (n = 340) | 9 ± 3% (n = 340) | 58 ± 6% (n = 267) | 34 ± 6% (n = 267) | 8 ± 3% (n = 267) |
EOI, end of induction.
a
From time of study entry.